For several decades etiological diagnosis of patients with idiopathic mental retardation (MR) and multiple congenital anomalies (MCA) has relied on chromosome analysis by karyotyping. Conventional karyotyping allows a genome-wide detection of chromosomal abnormalities but has a limited resolution. Recently, array-based comparative genomic hybridization (array CGH) technologies have been developed to evaluate DNA copy-number alterations across the whole-genome at a much higher resolution. It has proven to be an effective tool for detection of submicroscopic chromosome abnormalities causing congenital disorders and has recently been adopted for clinical applications. Here, we investigated four high-density array platforms with a theoretical resolution p100 kb: 33K tiling path BAC array, 500K Affymetrix SNP array, 385K NimbleGen oligonucleotide array and 244K Agilent oligonucleotide array for their robustness and implementation in our diagnostic setting. We evaluated the practical performance based on the detection of 10 previously characterized abnormalities whose size ranged from 100 kb to 3 Mb. Furthermore, array data analysis was performed using four computer programs developed for each corresponding platform to test their effective ability of reliable copy-number detection and their user-friendliness. All tested platforms provided sensitive performances, but our experience showed that accurate and user-friendly computer programs are of crucial importance for reliable copy-number detection.
Introduction
Cytogenetic analysis for etiological diagnosis of patients with developmental delay and birth defects has since the 1970s relied on chromosome banding by karyotyping for whole-genome analysis. However, conventional karyotyping allows genome-wide detection of chromosomal abnormalities at a limited resolution (5) (6) (7) (8) (9) (10) . This problem can be overcome by using high-resolution screening technologies such as the recently developed arraybased comparative genomic hybridization (array CGH). This technique is based on the competitive hybridization of reference and patient DNA samples to an immobilized target sequence on a glass slide or other solid platform. It allows a simultaneous evaluation of DNA copy-number alterations associated with chromosome abnormalities across the whole genome. Over the past years, array CGH has proven to be a powerful tool for detection of submicroscopic chromosome abnormalities in patients with idiopathic mental retardation (MR) and/or multiple congenital anomalies (MCA). 1 -10 These studies have led to the transfer of this research tool into a diagnostic instrument and a rapidly increasing number of clinical genetic laboratories offering array CGH as a genetic diagnostic service. The early stage experiences using array CGH were mostly based on 'in-house' produced bacterial artificial chromosome (BAC) arrays consisting of largeinsert clones with an initial coverage of approximately one clone per Mb. 2 -5,7,8 With the majority of causal submicroscopic alterations detected randomly distributed across the genome, 1 -10 it is clear that whole-genome microarray is preferred over targeted microarray when investigating idiopathic MR. The added value of genome-wide highresolution array CGH analysis over targeted arrays was recently discussed by Veltman and de Vries.
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Recent developments in genome-wide array CGH technologies using oligonucleotides and single-nucleotide polymorphisms (SNPs) have resulted in a new generation of genome-wide array platforms. Several commercially available platforms containing a larger number of shorter DNA fragments (oligonucleotides) can now be used to interrogate the whole genome at an increased resolution. However, an adequate description of the capability of each platform has been difficult to define since the resolution of the array is not only determined by the number and size of probes, but more importantly by the genomic spacing and the hybridization sensitivity of the probes on the array. This makes platform comparison confusing as the increased number of array elements does not automatically result in a linear increase of performance that gives an experimental resolution that deviates from the theoretical resolution. The aim of this study was to validate the performance of four high-density array platforms for copynumber detection, based on the ability to detect submicroscopic constitutional chromosome abnormalities with the purpose of implementing a commercially available platform into our clinical diagnostic setting.
Materials and methods

Material selection
To investigate the performance of four different array CGH platforms based on their detection of causal genomic imbalances, we selected cases with well-characterized submicroscopic constitutional chromosome aberrations. Eight cases consisting of 10 deletions and/or duplications ranging in size from 100 kb to 3.0 Mb with different genomic locations were used in this study ( Table 1 ). The majority of genomic imbalances (6 out of 10) were located on chromosomes 22 and 17 since these two chromosomes are known to harbor a large number of genomic structures, such as segmental duplications that predispose for genomic rearrangements. The 10 abnormalities consisted of 3 interstitial microduplications (sizing 500, 637 and 800 kb), 3 interstitial microdeletions (sizing 1.5, 1.6 and 3.0 Mb), 3 terminal deletions (sizing 100 kb, 1.7 and 2.3 Mb) and 1 terminal duplication (1.3 Mb). Chromosome imbalances of cases 1, 4, 5, 6 and 7 had initially been identified using 33K BAC array CGH platform, while the abnormalities of cases 2, 3 and 8 had been detected by subtelomeric fluorescence in situ hybridization (FISH). All abnormalities had been confirmed and further mapped to B100 kb accuracy using locus-specific BAC FISH or synthetic probe multiplex ligation-dependent probe amplification. The amount of cells having a deletion in the mosaic case (case 5) had been determined using interfase FISH by investigation of 200 nuclei. Two of the rearrangements (637 kb duplication at Xp21.2 and 100 kb deletion at 22q13.3) were accurately mapped to the base pair level by PCR and sequencing, 12, 13 and five of the cases (cases 2, 3, 6, 7 and 8) have been previously reported. 13 -17 To investigate the performance according to the ability to detect small but clinically significant genomic imbalances, all selected abnormalities included in this study were most likely causal for the phenotypes in the patients except for the de novo 500-kb duplication on 9p in case 6 that had no reported normal variants in this region at the time of investigation and was reported with an unclear clinical significance. 17 They were all de novo genomic alterations (except case 7, which had a causal maternally inherited duplication 13 ), and none of the imbalances had previously been reported as a normal variant except the duplication in case 6. 18 with additional clones located in the telomeric regions 19 and clones covering microdeletion syndromes. 5 The arrays were printed as previously described. 20 BAC clones were mapped according to the UCSC Human
DNA preparation
Genome browser May 2004. Sample labeling and hybridization were performed as described previously, 21 and the arrays where scanned using GenePixs Professional 4200A scanner (Axon Instruments, Union City, CA, USA). Identification of individual spots on scanned arrays was performed with GenePix Pro 6.0 (Axon Instruments) and the quantified data matrix was loaded into BioArray Software Environment BASE. 22 For breakpoint identification, a BASE plug-in GLAD 23 was used and the threshold for gains and losses was set to Z3 consecutive clones with log 2 (ratio) of ± 0.2. Color reverse experiments were performed.
Affymetrix 500K GeneChip
The Affymetrix 500K GeneChip array contains 25-mer oligonucleotides distributed over two subarrays containing 262 264 and 238 304 SNPs, respectively, representing a total of 500 568 SNPs was used. The median SNP spacing is B2.5 kb. Each subarray interrogates SNPs residing NspI or StyI PCR amplicons that range in size from 200 to 1000 bp. Experiments were performed according to protocols provided by the manufacturer (Affymetrix Inc., Santa Clara, CA, USA). Raw copy numbers were estimated using CNAG software version 2.0 available at http://www.genome.umin.jp/CNAGtop2.html. 24 SNP data of 48 samples were downloaded from Affymetrix (http://www.affymetrix.com/ support/technicalsample_data/500K_data.affx) and were used as unpaired normal references. In addition, the raw copy-number values were calculated using the dChip software available at http://biosun1.harvard.edu/complab/dchip/, 25 and then a homemade script in R was applied to plot the values per chromosome across the genomic location for a more clear visualization of the imbalances. Each 250K array was analyzed separately, but for a more accurate breakpoint determination of each copy-number alteration, results from both chips were combined.
NimbleGen 385K oligonucleotide array
The 385K oligonucleotide array produced by NimbleGen Systems Inc. (Madison, WI, USA) was used. The array contains 386 165 isothermal oligonucleotides probes (45-to 85-mer with a median probe spacing of 6 kb) with complete genome coverage. Probe design, array fabrication, array CGH experiments including DNA labeling, hybridization, array scanning, data normalization and log 2 copy-number ratio calculation were performed by NimbleGen Systems Inc. Array data were analyzed using the SignalMap Software version 1.8 (NimbleGen Systems Inc.).
Agilent 244K oligonucleotide array
The 244K oligonucleotide array with complete genome coverage produced by Agilent Technologies (Wilmington, DE, USA) was used. The array contains 236 000 oligonucleotides probes (60-mer) plus 1000 triplicates and 5000 Submicroscopic constitutional chromosome aberrations Z-F Zhang et al controls with a median probe spacing of 8.9 kb. Experiments were performed according to the manufacturer's protocol. After hybridization and washing, the slides were scanned on an Agilent Microarray Scanner. Captured images were analyzed with Feature Extraction Software v 9.1 and CGH Analytics 3.4 (Agilent Technologies) as described previously by Fan et al.
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Array performance All hybridizations using the different platforms were successful and passed the quality criteria in each software package except for one hybridization on the Affymetrix 500K array (case 8), which most likely failed due to too low quantity of DNA (o500 ng). One microgram of genomic DNA was used for each hybridization (except for the Affymetrix platform, where 250 ng was used for each enzyme assay). Color reverse experiments were performed on the 33K tiling BAC array using 1 mg for each labeling and single hybridizations were performed on the other platforms. Labeling, hybridization, washing and scanning of the slides of each array platform were performed according to the recommendation of each manufacturer. Array CGH analysis was carried out using four different computer programs, developed and/or recommended for each platform. For two of the platforms, software especially developed for array CGH application were commercially available (CGH Analytics from Agilent and SignalMap from Nimblegen), while for the two other platforms we relied on academically developed software available online and free for public download. All abnormalities were analyzed blindly and the results of the array experiments are summarized in Table 1 .
Results
33K tiling path BAC arrays
The 33K tiling path array detected all abnormalities that were hybridized (cases 1 -7). Case 8, with a subtelomeric deletion of 100 kb, was not tested due to limited DNA quantity, and since the array only contained one clone in the 22q13.33 deleted region it was not expected to be detectable according to the threshold used in our analysis (three consecutive clones exceeding threshold log 2 ratio±0.2). Using the 33K BAC array, we observed an average CNV (copy-number variant present in healthy individuals) of eight per individual. In all, 6 out of 10 abnormalities were initially identified by the 33K BAC; therefore, this platform could not objectively be compared with the other three platforms.
Affymetrix 500K GeneChip
One out of eight 500K Affymetrix SNP array experiments failed to give good quality data (case 8 containing a 100-kb 22q13.33 deletion). Unfortunately, the experiment could not be repeated due to insufficient DNA quantity.
Therefore, it remains unclear whether the abnormality would have been detected due to the low coverage of probes (two probes on NspI and three probes on StyI) in the region on the 500K SNP array. First, copy-number analysis was blindly carried out using CNAG v 2.0. One abnormality, the 1.6-Mb mosaic deletion at 22q11.21, failed to be detected in this analysis (case 5, see Table 1 ). Second, analysis was performed using a dChip and an R script for a clearer visualization of the genomic imbalances for each chromosome. By visual inspection of the genomic region containing the expected abnormality, the 1.6-Mb deletion missed by the CNAG analysis was visible (Figure 1 ). An average of 20 CNVs per individual was observed using this platform.
NimbleGen 385K oligonucleotide array
All experiments on NimbleGen arrays were performed at NimbleGen Systems Iceland (Reykjavik, Iceland), and data were analyzed using SignalMap version 1.8 software. Eight hybridizations were performed using four arrays. Samples 3, 5, 6 and 8 were hybridized on 'reuse' arrays that were previously used on samples 1, 2, 4 and 7, respectively. The arrays were cleaned from genomic DNA prior to the second hybridization. Three abnormalities escaped detection using this platform; a 100-kb 22q13.33 deletion, a 500-kb 9p24.3 duplication and a 1.6-Mb mosaic 22q11.21, while all three regions had a dense probe coverage on the array. However, the three samples containing these abnormalities were all hybridized on a 'reuse' array. An average of 20 CNVs per individual was observed in the tested samples.
Agilent 244K oligonucleotide array
All abnormalities were correctly detected using the 244K Agilent platform and the CGH Analytics software. An average of 19 CNVs per individual was observed.
Discussion
Genome-wide copy-number detection using microarrays is becoming an indispensable genetic analysis in the diagnosis of idiopathic MR/MCA. Guidelines for molecular karyotyping in constitutional genetic diagnosis have been published. 26 However, the practical implementation of molecular karyotyping into the cytogenetic laboratory, for at least partial replacement of conventional karyotyping, is not an easy road. Bioinformaticians, to assist in array CGH analysis by designing specialized algorithms for reliable detection of copy-number alteration, are usually not accessible in a routine cytogenetic laboratory. Therefore, it is not only of great importance that arrays are subjected to test their reproducibility, but also the software used for analysis should be user-friendly and reliable for detection of gains and losses in the genome. Four different array platforms for copy-number detection were tested to investigate which of the high-density array platforms would be most suitable for implementation in our diagnostic setting. Microarray platform comparison is complex since its resolution is not only determined by the number, size and spacing of the array elements, but also depends on the signal-to-noise ratio of each probe. Statistical calculation to estimate the functional resolution instead of the theoretical resolution of various platforms have recently been reported. 27, 28 We validated the practical performance of different CGH platforms based on the detection of submicroscopic chromosome imbalances identified in patients with MR and/or birth defects, since we are targeting this group of patients by using highresolution genome-wide array analysis in our clinic.
Using the 33K tiling path BAC array, we detected on average 8 CNVs, while the other three platforms with increased resolution detected 19 -20 CNVs per individual. A drawback of genome-wide analysis at increased resolution is the increased detection of inherited submicroscopic CNVs from phenotypically normal parents, reflecting normal CNVs rather than disease-associated genomic changes. This initially complicated the discernment between a copy-number alteration that causes disease versus one without clinical consequences. However, since the first reports on normal large-scale copy-number variation in 2004, 29, 30 knowledge has dramatically improved by cataloging normal variation in several ethnic populations. 31, 32 By making the tremendous number of detected benign CNVs publicly accessible in a database at http://projects.tcag.ca/variation/, array analysis has been greatly facilitated. All CNVs observed in these eight patients were listed in the database of genomic variants and were therefore not subjected to further analysis. Using the 33K BAC array, nine out of nine abnormalities were detected (case 8 was not tested). However, six of the abnormalities were initially identified by this platform, and therefore the comparison to the other platforms was biased. In addition, the data from the 33K BAC were obtained from replicate analyses, while all other array data were obtained from a single hybridization per chip. The replicate analysis increases the reliability of results from the BAC array, while a single hybridization would be more sensitive for false positive results. Using the Agilent 244K array, 10 out of 10 abnormalities were correctly identified. The 385K NimbleGen array detected 7 out of 10. The 500K In addition, the patient has a common CNV at the centromere position (black arrow). (a) Represents the plot from the analysis by the 33K tiling path BAC array performed in BASE using breakpoint identification plug-in 'GLAD.' The results show the detection of the CNV at the centromere, the 1.6-Mb deletion (clones displayed in red) and the 800-kb duplication (clones displayed in green). The 1.6-Mb deletion shows a mean ratio value of 0.3, which indicates a mosaic deletion. (b) Displays a CGH plot from the 385K NimbleGen array analyzed by SignalMap. The CNV at the centromeric region and the duplication are detected (visualized by red bar deviating from normal). The mosaic deletion is not observed. (c) The plot of Affymetrix 500K data, using the CNAG analysis software (NspI assay) is shown. The CNV region is excluded from analysis and the 800-kb duplication is visible by the blue bar deviating from normal. The 1.6-Mb deletion is not detected. (d) The Affymetrix NspI SNP array data after analysis in dChip and R. Abnormalities are detected by visual inspection. The 800-kb duplication is clearly displayed, while a 1.6-Mb deletion is less clearly visible. (e) In this image, the plot of the Agilent 244K is shown using CGH Analytics software. The 1.6-Mb deletion and the 800-kb duplication are both observed (visible by the blue bar deviating from normal) and the plot indicates a mosaic deletion. The CNV at the centromeric region is not detected since only a few probes on the array were located in that region.
SNP Affymetrix array detected eight out of nine using the CNAG software and nine out of nine using dChip in combination with an R script. The failure to detect the mosaic deletion by the two platforms mentioned above is most likely due to the fact that the Affymetrix and NimbleGen analyses displayed a slightly noisier data (Figure 1) , compared with the BAC and the Agilent analyses. Despite the relatively large size of the deletion (1.6 Mb), it was only present in 70% of the cells. This might indicate that mosaic cases of small chromosome segments might slightly easier escape detection using the Affymetrix and the NimbleGen platform and their corresponding software. However, the detection of copy-number imbalances in samples containing different cell populations can most likely be improved for the Affymetrix platform by the use of in-house control references instead of the reference data from Affymetrix. Thus, the choice of reference samples significantly affects the copy-number ratios. It is therefore strongly recommended to use reference samples that represent the experiment conditions of the tested samples to increase the sensitivity of the array. On the other hand, the need for optimization of the analysis by using a large series of in-house performed controls makes the platform less user-friendly for implementation in a clinical setting.
The 500-kb 9p24.3 duplication was not detected by the NimbleGen array. This can be explained by the fact that the theoretical ratio of a duplication is three copies from the patient versus two copies from the reference, which is closer to the random noise level compared with deletions (ratio one copy from the patient versus two copies from the reference). Very small duplications are thus more difficult to discriminate from experimental noise. Finally, the 100-kb deletion at 22q13.33 was not detected by either the NimbleGen or Affymetrix array, most probably due to the quality of DNA.
Regarding computerized array data analysis using the different software packages, the commercially developed software from Agilent Technologies (CGH Analytics) and NimbleGen Inc. (SignalMap) were considered to be more user-friendly compared with the free downloadable software packages. The CGH Analytics software and BASE produced good illustrations of the abnormalities, which greatly facilitated the detection of copy-number changes (see Figure 1) . As expected, the size of each aberration was found to be slightly variable using different platforms (Table 1) , because it is determined by the genomic position of the array elements of each platform, which have different coverage and distribution.
An important advantage to consider for the Affymetrix SNP array over the other three platforms is the combination of loss-of-heterozygosity analysis together with the CGH analysis, which enables the detection of copy-number neutral chromosomal aberrations such as uniparental disomy.
In conclusion, the four platforms we tested provided good and sensitive performances. However, we observed a variable capacity between the different platforms to detect the submicroscopic genomic alterations based on the different software analysis used. For the transition of the array technology into the diagnostic laboratories, and the partial replacement of conventional karyotyping by molecular karyotyping, the laboratory personnel needs to be retrained to be able to perform array analysis on an increasing scale. Therefore, reliable and user-friendly computer programs are of crucial importance. In our study, we found the array software package from Agilent Technologies to be the most accurate and user-friendly.
